Axovant Sciences (AXON) Reaches New 52-Week Low at $1.78

Axovant Sciences Ltd (NASDAQ:AXON)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $1.78 and last traded at $1.77, with a volume of 735749 shares trading hands. The stock had previously closed at $1.94.

AXON has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research note on Thursday, October 19th. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Wednesday, January 31st. BidaskClub upgraded shares of Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 12th. Finally, Piper Jaffray Companies reiterated a “hold” rating on shares of Axovant Sciences in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.61.

The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. The company has a market capitalization of $208.96, a PE ratio of -0.83 and a beta of -0.97.

Several institutional investors and hedge funds have recently made changes to their positions in AXON. Schwab Charles Investment Management Inc. grew its position in shares of Axovant Sciences by 32.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 49,800 shares of the biotechnology company’s stock worth $1,155,000 after acquiring an additional 12,200 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Axovant Sciences by 27.0% during the second quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock worth $2,380,000 after acquiring an additional 21,801 shares during the last quarter. Legal & General Group Plc grew its position in shares of Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares during the last quarter. Swiss National Bank grew its position in shares of Axovant Sciences by 17.5% during the second quarter. Swiss National Bank now owns 53,600 shares of the biotechnology company’s stock worth $1,243,000 after acquiring an additional 8,000 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 355 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences (AXON) Reaches New 52-Week Low at $1.78” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/11/axovant-sciences-axon-reaches-new-52-week-low-at-1-78.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply